Clinical trial
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor…
NCT00396864 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00396864 |
|---|---|
| Title | Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma |
| Official title | Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Lymphomas |
| Intervention type | Drug |
| Interventions | NPI-0052 |
| Enrollment | 51 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Nov 8, 2006 |
| Last update posted | Nov 22, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: